You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

CLINICAL TRIALS PROFILE FOR ZINACEF


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ZINACEF

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00730938 ↗ The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery Completed Presbyterian Church East Africa Kikuyu Hospital N/A 2008-02-01 The study investigates whether placing an antibiotic inside the eye at the end of cataract surgery in children will reduce the amount of fibrin formation (fibrin formation can block the pupil and reduce vision). We hypothesize that the fibrin is caused by a low-level infection and could be prevented by the antibiotic.
NCT00818610 ↗ Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia Completed University Hospital, Geneva Phase 4 2009-01-01 The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
NCT00818610 ↗ Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia Completed Swiss National Fund for Scientific Research Phase 4 2009-01-01 The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
NCT01524081 ↗ Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures Completed The Faculty Hospital Na Bulovce Phase 3 2008-07-01 Aim of prospective randomized a placebo controlled study is to prove that in case of acute surgical procedure due to appendicitis, ileus of small bowel and perforation of small bowel and stomach appropriately administered antibiotic prophylaxis is effective with lower incidence of infection in surgical site and comparable risk of development of other nosocomial infections versus group without antibiotic prophylaxis. Secondary aim is to determine risk of developing nosocomial infection in the above mentioned group of patients, identify group of patients which does not benefit from prophylaxis, and compile financial costs for antibiotic prophylaxis and treatment of nosocomial infections and thus the background for the recommended procedure with regards that such prospective study does not exist in the Czech Republic.
NCT02789579 ↗ The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy Unknown status Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Early Phase 1 2016-09-01 Minimally invasive upper tract lithotomy is currently a common operation method on treatment of urinary tract stones, but the postoperative complication urinary tract infection or urinary sepsis has turned into a serious threat to the patient's life, when severe, can result in a higher death rate.Although more the more importance were attached to, an effective prevention measures still have not been found. Among Urinary calculi, the higher rates of infection stone resulted in a higher incidence of postoperative urinary tract infection. The conventional postoperative prophylaxis medicine was the use of antimicrobial drugs half an hour before surgery.Foreign studies had shown that continuous preoperative one week use of nitrofurantoin can significantly reduce the incidence of urinary sepsis. So the investigators assume that preoperative extended use time of prophylaxis antibiotic may reduce the incidence of urinary tract infection or urinary sepsis. This study uses a computerized random method. According to preoperative use of different antimicrobial drug or treatment, all patients are randomly divided into five groups, namely levofloxacin 3days group,levofloxacin 7days group, nitrofurantoin 3days group,nitrofurantoin 7days group and cefuroxime group.The levofloxacin group receives levofloxacin 0.5g, qd, po, the nitrofurantoin group was given oral nitrofurantoin 100mg, tid, po.to explore the better antibiotics types, medication timing and duration of treatment to prevent postoperative infection after minimally invasive upper tract lithotomy, so as to reduce the incidence of postoperative urinary tract infection or sepsis.
NCT04212078 ↗ Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime Recruiting Santen Pharmaceutical Co., Ltd. Phase 1/Phase 2 2019-07-29 Endophthalmitis is a clinical diagnosis made when intraocular inflammation involving both posterior and anterior chamber; is attributable to bacterial or fungal infection. It is a serious intraocular inflammatory disorder which can be spread via endogenous or exogenous access into the eye by infecting organism. Exogenous spread usually happens post intraocular surgery or procedure (i.e. cataract, vitrectomy, glaucoma filtration surgery) while endogenous spread is associated with hematogenous spread. The occurrence of endophthalmitis accounts for serious post-operative complication which can lead to severe vision loss and even blindness. There are several studies conducted to ascertain the efficiency of intracameral antibiotic as post-operative endophthalmitis prophylaxis. However, there is limited study in human using intracameral levofloxacin to evaluate its effect.This study is designed to compare between intracameral levofloxacin and intracameral cefuroxime in terms of corneal endothelial cell count and its morphology and central corneal thickness in uncomplicated phacoemulsification surgery
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZINACEF

Condition Name

Condition Name for ZINACEF
Intervention Trials
Acute Appendicitis 1
Cataract 1
Community-acquired Pneumonia 1
Complication of Surgical Procedure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZINACEF
Intervention Trials
Endophthalmitis 2
Peptic Ulcer 1
Intestinal Obstruction 1
Appendicitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZINACEF

Trials by Country

Trials by Country for ZINACEF
Location Trials
Netherlands 2
Switzerland 2
Kenya 1
China 1
Czech Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZINACEF

Clinical Trial Phase

Clinical Trial Phase for ZINACEF
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZINACEF
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZINACEF

Sponsor Name

Sponsor Name for ZINACEF
Sponsor Trials
University Hospital, Geneva 1
Swiss National Fund for Scientific Research 1
The Faculty Hospital Na Bulovce 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZINACEF
Sponsor Trials
Other 7
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.